Evaluating real-world COVID-19 vaccine effectiveness using a test-negative case-control design.
J Comp Eff Res
; 11(16): 1161-1172, 2022 11.
Article
em En
| MEDLINE
| ID: mdl-36148919
ABSTRACT
Aim:
It is important to assess if clinical trial efficacy translates into real-world effectiveness for COVID-19 vaccines. Materials &methods:
We conducted a modified test-negative design (TND) to evaluate the real-world effectiveness of three COVID-19 vaccines. We defined cases in two ways self-reported COVID-19-positive tests, and self-reported positive tests with ≥1 moderate/severe COVID-19 symptom.Results:
Any vaccination was associated with a 95% reduction in subsequently reporting a positive COVID-19 test, and a 71% reduction in reporting a positive test and ≥1 moderate/severe symptom.Conclusion:
We observed high effectiveness across all three marketed vaccines, both for self-reported positive COVID-19 tests and moderate/severe COVID-19 symptoms. This innovative TND approach can be implemented in future COVID-19 vaccine and treatment real-world effectiveness studies. Clinicaltrials.gov identifier NCT04368065.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Vacinas contra COVID-19
/
COVID-19
Tipo de estudo:
Clinical_trials
/
Observational_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Revista:
J Comp Eff Res
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Estados Unidos